Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes

Gregory P. Levin, Cassianne Robinson-Cohen, Ian H. De Boer, Denise K. Houston, Kurt Lohman, Yongmei Liu, Stephen B. Kritchevsky, Jane A. Cauley, Toshiko Tanaka, Luigi Ferrucci, Stefania Bandinelli, Kushang V. Patel, Emil Hagström, Karl Michaëlsson, Håkan Melhus, Thomas Wang, Myles Wolf, Bruce M. Psaty, David Siscovick, Bryan Kestenbaum

Research output: Contribution to journalArticle

Abstract

Context: Lower serum 25-hydroxyvitaminDconcentrations are associatedwith greater risks of many chronic diseases across large, prospective community-based studies. Substrate 25-hydroxyvitamin D must be converted to 1,25-dihydroxyvitamin D for full biological activity, and complex metabolic pathways suggest that interindividual variability in vitamin D metabolism may alter the clinical consequences of measured serum 25-hydroxyvitamin D. Objective: To investigate whether common variation within genes encoding the vitamin D-binding protein, megalin, cubilin, CYP27B1, CYP24A1, and the vitamin D receptor (VDR) modify associations of low 25-hydroxyvitamin D with major clinical outcomes. Design, Setting, and Participants: Examination of 141 single-nucleotide polymorphisms in a discovery cohort of 1514 white participants (who were recruited from 4 US regions) from the community-based Cardiovascular Health Study. Participants had serum 25-hydroxyvitamin D measurements in 1992-1993 and were followed up for a median of 11 years (through 2006). Replication meta-analyses were conducted across the independent, community-based US Health, Aging, and Body Composition (n=922; follow-up: 1998-1999 through 2005), Italian Invecchiare in Chianti (n=835; follow-up: 1998-2000 through 2006), and Swedish Uppsala Longitudinal Study of Adult Men (n=970; follow-up: 1991-1995 through 2008) cohort studies. Main OutcomeMeasure: Composite outcome of incident hip facture, myocardial infarction, cancer, and mortality over long-term follow-up. Results: Interactions between 5 single-nucleotide polymorphisms and low 25-hydroxyvitamin D concentration were identified in the discovery phase and 1 involving a variant in the VDR gene replicated in independent meta-analysis. Among Cardiovascular Health Study participants, low 25-hydroxyvitamin D concentration was associated with hazard ratios for risk of the composite outcome of 1.40 (95% CI, 1.12-1.74) for those who had 1 minor allele at rs7968585 and 1.82 (95% CI, 1.31-2.54) for those with 2 minor alleles at rs7968585. In contrast, there was no evidence of an association (estimated hazard ratio, 0.93 [95% CI, 0.70-1.24]) among participants who had 0 minor alleles at this single-nucleotide polymorphism. Conclusion: Known associations of low 25-hydroxyvitamin D with major health outcomes may vary according to common genetic differences in the vitamin D receptor.

Original languageEnglish (US)
Pages (from-to)1898-1905
Number of pages8
JournalJournal of the American Medical Association
Volume308
Issue number18
DOIs
StatePublished - Nov 14 2012
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes'. Together they form a unique fingerprint.

  • Cite this

    Levin, G. P., Robinson-Cohen, C., De Boer, I. H., Houston, D. K., Lohman, K., Liu, Y., Kritchevsky, S. B., Cauley, J. A., Tanaka, T., Ferrucci, L., Bandinelli, S., Patel, K. V., Hagström, E., Michaëlsson, K., Melhus, H., Wang, T., Wolf, M., Psaty, B. M., Siscovick, D., & Kestenbaum, B. (2012). Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. Journal of the American Medical Association, 308(18), 1898-1905. https://doi.org/10.1001/jama.2012.17304